{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:19:48Z","timestamp":1761765588935},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T00:00:00Z","timestamp":1345161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s10147-012-0453-1","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T01:55:14Z","timestamp":1345082114000},"page":"922-926","source":"Crossref","is-referenced-by-count":6,"title":["Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-\u03b1 therapy"],"prefix":"10.1007","volume":"18","author":[{"given":"Yufeng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banghe","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,17]]},"reference":[{"key":"453_CR1","first-page":"1","volume":"24","author":"P Guglielmelli","year":"2010","unstructured":"Guglielmelli P, Vannucchi AM (2010) Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. Med Rep 24:1\u20136","journal-title":"Med Rep"},{"key":"453_CR2","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","volume":"22","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P (2008) Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22:1990\u20131998","journal-title":"Leukemia"},{"key":"453_CR3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/asheducation-2008.1.76","volume":"2008","author":"RL Levine","year":"2008","unstructured":"Levine RL, Heaney M (2008) New advances in the pathogenesis and therapy of essential thrombocythemia. Hematol Am Soc Hematol Educ Program 2008:76\u201382","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"453_CR4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11899-011-0109-7","volume":"7","author":"G Barosi","year":"2012","unstructured":"Barosi G, Lupo L, Rosti V (2012) Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. Curr Hematol Malig Rep 7:50\u201356","journal-title":"Curr Hematol Malig Rep"},{"key":"453_CR5","first-page":"1413","volume":"122","author":"Y Li","year":"2009","unstructured":"Li Y, Deng Z, Xuan H et al (2009) Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. Chin Med J (Engl) 122:1413\u20131417","journal-title":"Chin Med J (Engl)"},{"key":"453_CR6","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3109\/10428190903216838","volume":"50","author":"Y Li","year":"2009","unstructured":"Li Y, Liu X, Liu D et al (2009) The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy. Leuk Lymphoma 50:1889\u20131891","journal-title":"Leuk Lymphoma"},{"key":"453_CR7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00280-008-0805-8","volume":"63","author":"RM Stone","year":"2009","unstructured":"Stone RM, Donohue KA, Stock W et al (2009) A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 63:859\u2013864","journal-title":"Cancer Chemother Pharmacol"},{"key":"453_CR8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","volume":"109","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Garcia-Maner G et al (2007) Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109:248\u2013255","journal-title":"Cancer"},{"key":"453_CR9","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2009.52","volume":"23","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Michaels S et al (2009) Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 23:1446\u20131454","journal-title":"Leukemia"},{"key":"453_CR10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/138161211795049778","volume":"17","author":"M Wetzler","year":"2011","unstructured":"Wetzler M, Segal D (2011) Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 17:59\u201364","journal-title":"Curr Pharm Des"},{"key":"453_CR11","unstructured":"Vardiman JW, Brunning RD, Harris NL (2001) WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumors: tumours of the haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer (IARC) Press, pp 17\u201344"},{"key":"453_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2008","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2008) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951","journal-title":"Blood"},{"key":"453_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/asheducation-2010.1.129","volume":"2010","author":"C Harrison","year":"2010","unstructured":"Harrison C (2010) Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. Hematol Am Soc Hematol Educ Program 2010:129\u2013134","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"453_CR14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761\u2013770","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"453_CR15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbmt.2006.11.003","volume":"13","author":"R Hoffman","year":"2007","unstructured":"Hoffman R, Prchal JT, Samuelson S et al (2007) Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant 13(Suppl 1):64\u201372","journal-title":"Biol Blood Marrow Transplant"},{"key":"453_CR16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/138945011794815275","volume":"12","author":"HC Hasselbalch","year":"2011","unstructured":"Hasselbalch HC, Larsen TS, Riley CH et al (2011) Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 12:392\u2013419","journal-title":"Curr Drug Targets"},{"key":"453_CR17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3324\/haematol.2009.021444","volume":"95","author":"E Antonioli","year":"2010","unstructured":"Antonioli E, Carobbio A, Pieri L et al (2010) Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica 95:1435\u20131438","journal-title":"Haematologica"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0453-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-012-0453-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0453-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:37:28Z","timestamp":1559111848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-012-0453-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,17]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1007\/s10147-012-0453-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,17]]}}}